Nicotinamide Mononucleotide (NMN) for Insulin Resistance
Current human evidence does not show that nicotinamide mononucleotide (NMN) reliably improves insulin resistance. A single small trial reported a benefit, but the largest pooled analysis found none, so NMN cannot be recommended for blood-sugar or insulin-sensitivity goals.
Why this grade7-layer evidence engine
This claim earns a weak grade because the human data are thin and largely null. The most comprehensive evidence, a 2024 systematic review and meta-analysis of 8 RCTs (n=342, PMID 39531138), found no significant effect of NMN on fasting glucose, fasting insulin, HbA1c, or HOMA-IR; a small apparent HOMA-IR reduction disappeared after one outlier study was removed in sensitivity analysis.
The lone positive signal comes from a single tiny trial (PMID 33888596), in which 250 mg/day for 10 weeks raised muscle insulin sensitivity in just 25 prediabetic postmenopausal women. This result is narrow, unreplicated, and not generalizable. A separate dose-ranging RCT in 80 healthy middle-aged adults (PMID 36482258) found no HOMA-IR difference at 300-900 mg/day, and that trial was industry-funded, adding a conflict-of-interest caveat.
Regulators have addressed safety, not benefit: the FDA states NMN is excluded from the definition of a dietary supplement, and EFSA judged 300 mg/day safe for most adults (excluding pregnant and lactating women) without endorsing any health effect. Independent references such as Examine grade NMN poorly for metabolic outcomes, reinforcing that proven benefit for insulin resistance is lacking.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.423
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status